133 related articles for article (PubMed ID: 36208247)
41. The prognostic value of splenic abnormalities in pretreatment
Wang S; Ju H; Bai Y; Wang L; Ding Q; Li P; Jiang X; Lin X
Clin Radiol; 2023 May; 78(5):375-380. PubMed ID: 36805286
[TBL] [Abstract][Full Text] [Related]
42. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
[TBL] [Abstract][Full Text] [Related]
43. (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.
Mylam KJ; Kostakoglu L; Hutchings M; Coleman M; Lamonica D; Czuczman MS; Diehl LF; Nielsen AL; Jensen P; Loft A; Hendel HW; Iyer V; Leppä S; Jyrkkiö S; Holte H; Eriksson M; Gillstrøm D; Hansen PB; Seppänen M; Hjorthaug K; Brown Pde N; Pedersen LM
Leuk Lymphoma; 2015 Jul; 56(7):2005-12. PubMed ID: 25330442
[TBL] [Abstract][Full Text] [Related]
44. Predicting diffuse large B-cell lymphoma outcomes with lesion-to-liver maximum standardized uptake value for interim-treatment and end-of-treatment positron emission tomography-computed tomography.
Wang L; Zhang S; Xin J
Quant Imaging Med Surg; 2023 Oct; 13(10):6789-6800. PubMed ID: 37869355
[TBL] [Abstract][Full Text] [Related]
45. Combined Visual and Semiquantitative Evaluation Improves Outcome Prediction by Early Midtreatment
Györke T; Carr R; Cerci JJ; Meneghetti C; Redondo F; Celli M; Gorospe C; Auewarakul CU; Jorgov L; Paez D; Fanti S
J Nucl Med; 2020 Jul; 61(7):999-1005. PubMed ID: 31757842
[TBL] [Abstract][Full Text] [Related]
46. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma.
Akkas BE; Vural GU
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371
[TBL] [Abstract][Full Text] [Related]
47. Prognostic value of metabolic tumor volume and lesion dissemination from baseline PET/CT in patients with diffuse large B-cell lymphoma: Further risk stratification of the group with low-risk and high-risk NCCN-IPI.
Xu H; Ma J; Yang G; Xiao S; Li W; Sun Y; Sun Y; Wang Z; Zhao H
Eur J Radiol; 2023 Jun; 163():110798. PubMed ID: 37030099
[TBL] [Abstract][Full Text] [Related]
48. Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma.
Fuertes S; Setoain X; Lopez-Guillermo A; Carrasco JL; Rodríguez S; Rovira J; Pons F
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):496-504. PubMed ID: 23344136
[TBL] [Abstract][Full Text] [Related]
49. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax.
Itti E; Meignan M; Berriolo-Riedinger A; Biggi A; Cashen AF; Véra P; Tilly H; Siegel BA; Gallamini A; Casasnovas RO; Haioun C
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1312-20. PubMed ID: 23649463
[TBL] [Abstract][Full Text] [Related]
50. To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma).
Gupta N; Singh N
Nucl Med Commun; 2020 Apr; 41(4):395-404. PubMed ID: 32073552
[TBL] [Abstract][Full Text] [Related]
51. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era.
Yang DH; Ahn JS; Byun BH; Min JJ; Kweon SS; Chae YS; Sohn SK; Lee SW; Kim HW; Jung SH; Kim YK; Kim HJ; Bom HS; Lee JJ
Ann Hematol; 2013 Apr; 92(4):471-9. PubMed ID: 23238895
[TBL] [Abstract][Full Text] [Related]
52. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
[TBL] [Abstract][Full Text] [Related]
53. Progression Free Survival and Predictor of Recurrence in DLBCL patients with Negative Interim 18FDG PET/CT Using Standardized Imaging and Reporting Protocols.
Zaman MU; Fatima N; Zaman A; Zaman U; Zaman S; Tahseen R
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2343-2348. PubMed ID: 32856864
[TBL] [Abstract][Full Text] [Related]
54. Prognostic Value of Pre-Autologous Stem Cell Transplantation PET/CT in Diffuse Large B-Cell Lymphoma: The Deauville Score Is Prognostically Superior to ΔSUVmax.
Zhang XY; Song L; Wang PJ; Wang L; Li Y; Wang YY; Shi CL
Acta Haematol; 2020; 143(2):124-130. PubMed ID: 31382264
[TBL] [Abstract][Full Text] [Related]
55. Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with the SUV
Fan Y; Zhang Y; Yang Z; Ying Z; Zhou N; Liu C; Song Y; Zhu J; Wang X
Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28535082
[TBL] [Abstract][Full Text] [Related]
56. Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma.
Baek DW; Cho HJ; Kim JH; Sohn SK; Song GY; Ahn SY; Jung SH; Ahn JS; Lee JJ; Kim HJ; Jeong SY; Hong CM; Min JJ; Moon JH; Yang DH
In Vivo; 2020; 34(4):2127-2134. PubMed ID: 32606193
[TBL] [Abstract][Full Text] [Related]
57. Value of 18F-FDG PET/CT for early prediction of pathologic response (by residual cancer burden criteria) of locally advanced breast cancer to neoadjuvant chemotherapy.
Lee SM; Bae SK; Kim TH; Yoon HK; Jung SJ; Park JS; Kim CK
Clin Nucl Med; 2014 Oct; 39(10):882-6. PubMed ID: 25072926
[TBL] [Abstract][Full Text] [Related]
58. A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [
Zhang X; Chen L; Jiang H; He X; Feng L; Ni M; Ma M; Wang J; Zhang T; Wu S; Zhou R; Jin C; Zhang K; Qian W; Chen Z; Zhuo C; Zhang H; Tian M
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1298-1310. PubMed ID: 34651227
[TBL] [Abstract][Full Text] [Related]
59. FDG PET/CT response in diffuse large B-cell lymphoma: Reader variability and association with clinical outcome.
Han EJ; O JH; Yoon H; Jung SE; Park G; Choi BO; Cho SG
Medicine (Baltimore); 2016 Sep; 95(39):e4983. PubMed ID: 27684851
[TBL] [Abstract][Full Text] [Related]
60. Combined prognostic role of TARC and interim
Husi K; Pinczés LI; Fejes Z; Nagy B; Illés Á; Miltényi Z
Hell J Nucl Med; 2022; 25(2):125-131. PubMed ID: 35913858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
